Search for Stocks /

Artemis Medicare Services Ltd Q3 FY26 – ₹267 Cr Quarterly Revenue, 17.7% Growth, 700+ Beds Online, and a ₹700 Cr Fundraise Brewing

Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.

1. At a Glance

Artemis Medicare Services Ltd is what happens when a hospital quietly compounds for a decade and the market suddenly wakes up late. With a market cap of ₹3,778 crore, a current price of ₹239, and a Stock P/E of 38, Artemis sits awkwardly between “mid-cap healthcare darling” and “still ignored cousin of Apollo.”

Q3 FY26 numbers were clean and boring in the best possible way: ₹267 crore quarterly revenue (+17.7% YoY) and ₹24.8 crore PAT (+19.6% YoY). No drama, no accounting gymnastics, just beds filling up and bills getting paid. Operating margins hovered around 16%, ROCE at 14.9%, and debt-to-equity stayed disciplined at 0.31 despite aggressive expansion.

But the real headline isn’t the numbers—it’s the ambition. A third tower already commissioned in Gurugram, Raipur coming up in FY26, and a massive 550+ bed VIMHANS hospital in South Delhi planned. Oh, and the board casually approved a ₹700 crore fundraise.

So the question is simple: is Artemis still a single-hospital story, or is it trying to crash the big boys’ ICU party?


2. Introduction

Hospitals are boring businesses—until they’re not. Artemis Medicare spent years being the “nice, well-run hospital in Gurgaon” while investors chased shinier chains with louder PR. Meanwhile, Artemis just kept doing the unsexy stuff: improving ARPOB, expanding specialties, attracting international patients, and quietly adding beds.

Promoted by the Apollo Tyres Group, Artemis didn’t rush into reckless asset-heavy expansion. Instead, it built depth before width—first mastering Gurugram, then slowly stepping outside NCR. Now, suddenly, there’s a 700+ bed flagship, a greenfield hospital in Raipur, and a takeover-style expansion into South Delhi.

Financially, this isn’t a turnaround story—it’s a compounding story. Sales grew at ~19% CAGR over 3 years, profits at ~36% CAGR, and FY25 closed with ₹1,022 crore revenue and ₹99.4 crore PAT.

Yet the stock is down 24% over 1 year. Why? Promoter dilution, capex anxiety, and the market’s eternal fear of hospitals raising money.

So let’s dissect this properly—beds, bills, balance sheet, and all the juicy governance bits.


3. Business Model – WTF Do They Even Do?

At its core, Artemis does one thing very well: monetize hospital beds

Read Full 16 Point breakdown. Continue reading →
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →